Literature DB >> 23982274

A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy.

Junting Huang1, Yaojun Zhang, Zhenwei Peng, Hengjun Gao, Li Xu, Long R Jiao, Minshan Chen.   

Abstract

OBJECTIVE: To evaluate the accuracy of the 7th edition of the American Joint Committee on Cancer staging system (TNM-7) for patients undergoing hepatectomy for hepatocellular carcinoma (HCC) and to propose a modified TNM system for better prediction of survival.
METHODS: Clinico-pathological data for 1,313 patients who underwent hepatectomy as initial treatment for HCC between 2000 and 2008 were retrieved from a prospective database. Overall survival (OS) and disease-free survival (DFS) were analyzed to evaluate the predictive value.
RESULTS: The 1-, 3-, 5-year OS and DFS of 1,313 patients were 79.2, 55.4, 45.5 %, and 52.6, 36.1, 31.8 %, respectively. Multivariate analysis revealed that major vascular invasion was the most important prognostic factor for both OS and DFS, along with tumour number and size. Patients with pT1 and pT2 disease had significantly better OS and DFS than those with pT3 disease (P < 0.001). There was no significant difference between pT3a and pT4 (P = 0.552) but patients with pT3b disease had a worse OS and DFS than those with pT4 disease (P = 0.006 and P < 0.001, respectively). A modified TNM system within the existing framework was proposed to combine the current pT3a and pT4 together as the new pT3 and to change pT3b to the new pT4. Analysis showed that this modified system had a better prognostic power than either TNM-6 or TNM-7.
CONCLUSION: TNM-7 would seem to be inaccurate for staging advanced HCC. The modified system can improve both the prognostic accuracy and the hazard discrimination of disease to be consistent among subgroups of HCC.

Entities:  

Mesh:

Year:  2013        PMID: 23982274     DOI: 10.1007/s00432-013-1497-y

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  27 in total

1.  Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma.

Authors:  J M Llovet; J Bruix
Journal:  Hepatology       Date:  2000-09       Impact factor: 17.425

2.  Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.

Authors:  S Arii; Y Yamaoka; S Futagawa; K Inoue; K Kobayashi; M Kojiro; M Makuuchi; Y Nakamura; K Okita; R Yamada
Journal:  Hepatology       Date:  2000-12       Impact factor: 17.425

Review 3.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  Major achievements in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

5.  Portal venous invasion: the single most independent risk factor for immediate postoperative recurrence of hepatocellular carcinoma.

Authors:  Kang Kook Choi; Sung Hoon Kim; Sae Byeol Choi; Jin Hong Lim; Gi Hong Choi; Jin Sub Choi; Kyung Sik Kim
Journal:  J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 4.029

6.  Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan.

Authors:  Kwong-Ming Kee; Jing-Houng Wang; Chuan-Mo Lee; Chao-Long Chen; Chi-Sin Changchien; Tsung-Hui Hu; Yu-Fan Cheng; Hsuan-Chih Hsu; Chih-Chi Wang; Tai-Yi Chen; Chih-Yun Lin; Sheng-Nan Lu
Journal:  Int J Cancer       Date:  2007-06-15       Impact factor: 7.396

7.  Hepatocellular carcinoma in developing countries: Prevention, diagnosis and treatment.

Authors:  Michael C Kew
Journal:  World J Hepatol       Date:  2012-03-27

8.  Application of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?

Authors:  Binkui Li; Yunfei Yuan; Guihua Chen; Liru He; Yaqi Zhang; Jinqing Li; Guohui Li; Wan Yee Lau
Journal:  BMC Cancer       Date:  2010-10-07       Impact factor: 4.430

9.  Resection of hepatocellular carcinoma with diaphragmatic invasion.

Authors:  W Y Lau; K L Leung; T W Leung; C T Liew; M Chan; A K Li
Journal:  Br J Surg       Date:  1995-02       Impact factor: 6.939

10.  Evaluation of the new AJCC staging system for resectable hepatocellular carcinoma.

Authors:  Chih H Cheng; Chen F Lee; Tsung H Wu; Kun M Chan; Hong S Chou; Ting J Wu; Ming C Yu; Tse C Chen; Wei C Lee; Miin F Chen
Journal:  World J Surg Oncol       Date:  2011-09-30       Impact factor: 2.754

View more
  13 in total

1.  Number of nodules, Child-Pugh status, margin positivity, and microvascular invasion, but not tumor size, are prognostic factors of survival after liver resection for multifocal hepatocellular carcinoma.

Authors:  Brian K P Goh; Pierce K H Chow; Jin-Yao Teo; Jen-San Wong; Chung-Yip Chan; Peng-Chung Cheow; Alexander Y F Chung; London L P J Ooi
Journal:  J Gastrointest Surg       Date:  2014-05-23       Impact factor: 3.452

Review 2.  Staging systems for hepatocellular carcinoma: Current status and future perspectives.

Authors:  Akiyoshi Kinoshita; Hiroshi Onoda; Nao Fushiya; Kazuhiko Koike; Hirokazu Nishino; Hisao Tajiri
Journal:  World J Hepatol       Date:  2015-03-27

3.  2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2015-05-13       Impact factor: 3.500

Review 4.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Korean J Radiol       Date:  2019-07       Impact factor: 3.500

5.  2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2019-05-15       Impact factor: 4.519

6.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 7.  [Early stage liver cancer : Hepatocellular carcinoma].

Authors:  P R Scherber; G Gäbelein; R M Eisele; D Igna; M Glanemann
Journal:  Chirurg       Date:  2018-04       Impact factor: 0.955

8.  Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size.

Authors:  Cheng-Maw Ho; Rey-Heng Hu; Po-Huang Lee; Yao-Ming Wu; Ming-Chih Ho
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

9.  CHIC Risk Stratification System for Predicting the Survival of Children With Hepatoblastoma: Data From Children With Hepatoblastoma in China.

Authors:  Junting Huang; Yang Hu; Hong Jiang; Yanjie Xu; Suying Lu; Feifei Sun; Jia Zhu; Juan Wang; Xiaofei Sun; Juncheng Liu; Zijun Zhen; Yizhuo Zhang
Journal:  Front Oncol       Date:  2020-11-18       Impact factor: 6.244

10.  Vasohibin 2 decreases the cisplatin sensitivity of hepatocarcinoma cell line by downregulating p53.

Authors:  Zhanjun Li; Min Tu; Bei Han; Yuqing Gu; Xiaofeng Xue; Jie Sun; Qianqian Ge; Yi Miao; Zhuyin Qian; Wentao Gao
Journal:  PLoS One       Date:  2014-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.